These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35581243)

  • 1. Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites.
    Hirooka M; Koizumi Y; Yano R; Nakamura Y; Sunago K; Yukimoto A; Watanabe T; Yoshida O; Tokumoto Y; Abe M; Hiasa Y
    Sci Rep; 2022 May; 12(1):8124. PubMed ID: 35581243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Kida Y
    Dig Dis; 2019; 37(3):239-246. PubMed ID: 30625470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisterna chyli in autosomal dominant polycystic kidney disease.
    Thimmappa ND; Blumenfeld JD; Cerilles MA; Dunning A; Donahue SL; Bobb WO; Zhang HL; Prince MR
    J Magn Reson Imaging; 2015 Jan; 41(1):142-8. PubMed ID: 24470398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites.
    Kawaratani H; Sawai H; Onishi M; Kogiso T; Shimada N; Uojima H; Nakajima T; Matsumoto N; Ikejima K; Ishikawa T; Terai S; Motoyama H; Komori A; Hirashima N; Saito S; Eguchi Y; Nojima M; Kawai Y; Tateyama M; Yoshiji H; Tanaka Y
    Liver Int; 2021 Dec; 41(12):2944-2953. PubMed ID: 34309184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisterna chyli in patients with portal hypertension: evaluation with MR imaging.
    Ito K; Shimizu A; Tanabe M; Matsunaga N
    J Magn Reson Imaging; 2012 Mar; 35(3):624-8. PubMed ID: 22069241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic drainage dysfunction via narrowing of the lumen of cisterna chyli and thoracic duct after luminal dilation.
    Yano R; Hirooka M; Koizumi Y; Nakamura Y; Imai Y; Morita M; Okazaki Y; Watanabe T; Yoshida O; Tokumoto Y; Abe M; Hiasa Y
    Hepatol Int; 2023 Dec; 17(6):1557-1569. PubMed ID: 37500943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    Namba M; Hiramatsu A; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Tsuge M; Imamura M; Chayama K
    J Gastroenterol; 2020 Feb; 55(2):217-226. PubMed ID: 31485782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
    Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
    Atsukawa M; Tsubota A; Takaguchi K; Toyoda H; Iwasa M; Ikegami T; Chuma M; Nozaki A; Uojima H; Hiraoka A; Fukunishi S; Yokohama K; Tada T; Kato K; Abe H; Tani J; Okubo H; Watanabe T; Hattori N; Tsutsui A; Senoh T; Yoshida Y; Okubo T; Itokawa N; Nakagawa-Iwashita A; Kondo C; Arai T; Michitaka K; Iio E; Kumada T; Tanaka Y; Takei Y; Iwakiri K
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1229-1237. PubMed ID: 31881554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postural effect on the size of the cisterna chyli.
    Niggemann P; Förg A; Grosskurth D; Beyer HK
    Lymphat Res Biol; 2010 Dec; 8(4):193-7. PubMed ID: 21190491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    Sakaida I; Terai S; Kurosaki M; Okada M; Hirano T; Fukuta Y
    J Gastroenterol; 2020 Aug; 55(8):800-810. PubMed ID: 32388692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow in lymphatic networks: interaction between hepatic and intestinal lymph vessels.
    Stewart RH; Laine GA
    Microcirculation; 2001 Aug; 8(4):221-7. PubMed ID: 11528530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily Monitoring of Serum Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein Is Useful for Predicting Therapeutic Effect of Tolvaptan in Cirrhotic Ascites.
    Takamura M; Sakamaki A; Arao Y; Setsu T; Kamimura H; Yokoo T; Kamimura K; Tsuchiya A; Terai S
    Tohoku J Exp Med; 2020 Dec; 252(4):287-296. PubMed ID: 33208569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computed tomographic characteristics of the cisterna chyli in dogs.
    Birch S; Barberet V; Bradley K; Parsons K; Warren-Smith C
    Vet Radiol Ultrasound; 2014; 55(1):29-34. PubMed ID: 23941469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response criteria of tolvaptan for the treatment of hepatic edema.
    Hiramine Y; Uojima H; Nakanishi H; Hiramatsu A; Iwamoto T; Kimura M; Kawaratani H; Terai S; Yoshiji H; Uto H; Sakaida I; Izumi N; Okita K; Koike K
    J Gastroenterol; 2018 Feb; 53(2):258-268. PubMed ID: 28664229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term administration of Tolvaptan to patients with decompensated cirrhosis.
    Kanayama K; Chiba T; Kobayashi K; Koroki K; Maruta S; Kanzaki H; Kusakabe Y; Saito T; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Yasui S; Kanda T; Maruyama H; Kato J; Kato N
    Int J Med Sci; 2020; 17(7):874-880. PubMed ID: 32308540
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan.
    Adachi T; Takeuchi Y; Takaki A; Oyama A; Wada N; Onishi H; Shiraha H; Okada H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasonographic characteristics of the cisterna chyli in eight dogs and four cats.
    Etienne AL; Cavrenne R; Gommeren K; Bolen G; Busoni V
    Vet Radiol Ultrasound; 2013; 54(4):398-402. PubMed ID: 23662920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan.
    Osawa L; Nakanishi H; Kurosaki M; Kirino S; Inada K; Yamashita K; Hayakawa Y; Sekiguchi S; Wang W; Okada M; Higuchi M; Komiyama Y; Takaura K; Takada H; Kaneko S; Maeyashiki C; Tamaki N; Yasui Y; Tsuchiya K; Itakura J; Takahashi Y; Enomoto N; Izumi N
    Dig Dis; 2022; 40(4):479-488. PubMed ID: 34348262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.